NImmune Biopharma

Focus: NImmune Biopharma is a public small molecule immunology-focused pharmaceutical company headquartered in Blacksburg, VA, currently in early-stage clinical development with no approved products on market.

Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About NImmune Biopharma

AI assessmentNot Hiring

No open roles listed right now. Follow NImmune Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

BT-11 low

Eosinophilic Esophagitis

Phase 1

Clinical Trials (1)

NCT04835168Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis

Phase 1

Help build intelligence for NImmune Biopharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline in immunology offers opportunity to shape drug development strategy from Phase 1/2 stage before potential peak revenue
Public company status provides liquidity and access to capital markets, reducing pre-revenue biotech extinction risk
Small molecule focus in immunology represents active therapeutic area with multiple disease targets (IBD, EoE)

Watch Out For

Zero active job openings indicates company is not actively hiring or may be conserving resources during clinical development phase
No marketed products, approved revenue, or published data creates execution risk with no near-term commercial milestones visible

Generated by Claude from NImmune Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Placebo

Normal Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03860571Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers

Phase 1

NIM-1324

Normal Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT05019950Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers

Phase 1